L-글루타민 관련 크론병
C 근거 소규모 연구에서의 근거는 제한적이지만, 일부 긍정적인 신호가 존재합니다.소규모 RCT에서 글루타민(0.5g/kg/일)이 크론병 환자의 장 투과성과 형태를 개선하는 것으로 나타났습니다. 근거는 작은 표본 크기로 제한됩니다.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
소규모 RCT에서 글루타민(0.5g/kg/일)이 크론병 환자의 장 투과성과 형태를 개선하는 것으로 나타났습니다. 근거는 작은 표본 크기로 제한됩니다.
Key Study Findings
Other
Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease.
Dose: None
vs: None
Outcome: Gut microbiota composition
효과: None
None
대상 집단: Crohn's disease patients
Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None
vs: None
Outcome: Cholesterol levels
효과: None
None
대상 집단: Mouse model
Controlled Clinical Trial
Washed microbiota transplantation for Crohn's disease: A metagenomic, metatranscriptomic, and metabolomic-based study.
Dose: Washed microbiota transplantation (WMT)
vs: Pre-treatment baseline
Outcome: Clinical remission and multi-omics changes
효과: None
None
대상 집단: Patients with Crohn's disease
In Vitro
Constitutively active autophagy in macrophages dampens inflammation through metabolic and post-transcriptional regulation of cytokine production.
Dose: Beclin1 constitutive activation (genetic)
vs: Wild-type mice
Outcome: Cytokine production in macrophage activation
효과: None
None
대상 집단: Beclin1 variant mice + AIEC infection
Observational Study
n=262
Gut Microbiome-Generated Phenylacetylglutamine from Dietary Protein is Associated with Crohn's Disease and Exacerbates Colitis in …
Dose: Phenylacetylglutamine (PAGln, measured)
vs: Healthy controls (n=126)
Outcome: PAGln association with CD and colitis
효과: None
None
대상 집단: New-onset treatment-naive CD (n=136) + controls
Observational Study
COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN BRAZILIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
Dose: None
vs: None
Outcome: CAM use patterns in IBD patients
효과: None
None
대상 집단: Brazilian IBD patients
Key Statistics
3
연구
200
참여자
↑
Positive
C
등급
Referenced Papers
Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease.
Other
EMBO molecular medicine
2024
13 인용
Cannabis and cannabinoid …
2024
10 인용
World journal of …
2024
Cell reports
2023
27 인용
Journal of Crohn's …
2023
24 인용
JCI insight
2022
24 인용
Sheng wu gong …
2022
4 인용
COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN BRAZILIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
Other
Arquivos de gastroenterologia
2022
4 인용
Effects of glutamine supplementation on inflammatory bowel disease: A systematic review of clinical trials.
Systematic Review
Clinical nutrition ESPEN
2021
39 인용
Gastroenterology
2019
118 인용
Journal of cellular …
2019
23 인용
The Cochrane database …
2018
425 인용
Gastroenterology clinics of …
2018
67 인용
Clinical medicine insights. …
2018
15 인용
Nutrition in clinical …
2018
10 인용
Current opinion in …
2017
37 인용
JPEN. Journal of …
2017
24 인용
World journal of …
2017
21 인용
The AAPS journal
2017
Glutamine for induction of remission in Crohn's disease.
Systematic Review
The Cochrane database …
2016
37 인용
Scandinavian journal of …
2014
56 인용
Digestive diseases and …
2012
81 인용
Frontline gastroenterology
2012
20 인용
Plasma citrulline concentration as a marker for disease activity in patients with Crohn's disease.
Other
Journal of clinical …
2012
13 인용
Pediatrics in review
2012
International journal of …
2011
12 인용
Inflammatory bowel diseases
2010
89 인용
Nutricion hospitalaria
2010
Nutrition in clinical …
2009
36 인용
The Journal of …
2008
89 인용
Molecular nutrition & …
2008
26 인용
The Cochrane database …
2007
192 인용
Digestive diseases and …
2006
73 인용
Immunonutrition.
Review
Current opinion in …
2005
22 인용
JPEN. Journal of …
2005
19 인용
Clinical nutrition (Edinburgh, …
2004
18 인용
Medycyna wieku rozwojowego
2004
1 인용
Annali italiani di …
2004
Alimentary pharmacology & …
2003
179 인용
Nutricion hospitalaria
2003
Revista do Hospital …
2002
39 인용
Scandinavian journal of …
2002
28 인용
Enteral feeding.
Other
Current opinion in …
2002
1 인용
Enteral feeding.
Review
Current opinion in …
2002
Enteral nutritional therapy for inducing remission of Crohn's disease.
Systematic Review
The Cochrane database …
2001
149 인용
Journal of pediatric …
2000
187 인용
Current opinion in …
2000
21 인용
JPEN. Journal of …
2000
18 인용
JPEN. Journal of …
1999
129 인용
Diseases of the …
1998
26 인용
Zeitschrift fur Gastroenterologie
1998
18 인용
FASEB journal : …
1997
170 인용
Schweizerische medizinische Wochenschrift. …
1996
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 5-15 g/day
- ibsdsupport:
- 5 g three times daily (15 g/day total)
- postexercisegut:
- 0.25-0.9 g/kg before intense exercise
- gutbarriersupport:
- 0.5 g/kg/day (approximately 30-40 g/day for adults)
상한량: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| Washed microbiota transplantation (WMT) | -- | Positive | -- |
| Beclin1 constitutive activation (genetic) | -- | Positive | -- |
| Phenylacetylglutamine (PAGln, measured) | -- | Negative | 262 |
| None | -- | Mixed | -- |
| None | -- | Negative | -- |
| None | -- | Mixed | -- |
권장 복용 시간: Between meals or before exercise; divide doses throughout the day
Safety & Side Effects
보고된 부작용
- ⚠ Mild gastrointestinal discomfort at high doses
- ⚠ Headache
- ⚠ Dizziness at very high doses
- ⚠ Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)
알려진 상호작용
- ● Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
- ● Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
- ● Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)
일일 최대 섭취 허용량: Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does L-글루타민 help with 크론병?
Based on 3 studies with 200 participants, there is limited but promising evidence that L-글루타민 may support 크론병 management. Our evidence grade is C (Some Evidence).
How much L-글루타민 should I take for 크론병?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-글루타민?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-글루타민 and 크론병?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 크론병
L-글루타민 다른 건강 상태에 대한 근거
References
- [1] Xuehua Li et al.. EMBO Mol Med. 2024. Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn's disease. doi:10.1038/s44321-024-00129-8 PubMed
- [2] Mengxue He et al.. Cannabis Cannabinoid Res. 2024. Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes. doi:10.1089/can.2022.0331 PubMed
- [3] Shi-Ju Chen et al.. World J Gastroenterol. 2024. Washed microbiota transplantation for Crohn's disease: A metagenomic, metatranscriptomic, and metabolomic-based study. doi:10.3748/wjg.v30.i11.1572 PubMed
- [4] Jinjin Xu et al.. Cell Rep. 2023. Constitutively active autophagy in macrophages dampens inflammation through metabolic and post-transcriptional regulation of cytokine production. doi:10.1016/j.celrep.2023.112708 PubMed
- [5] Rui Feng et al.. J Crohns Colitis. 2023. Gut Microbiome-Generated Phenylacetylglutamine from Dietary Protein is Associated with Crohn's Disease and Exacerbates Colitis in Mouse Model Possibly via Platelet … doi:10.1093/ecco-jcc/jjad098 PubMed
- [6] Shiying Zhang et al.. JCI Insight. 2022. Mucosal metabolites fuel the growth and virulence of E. coli linked to Crohn's disease. doi:10.1172/jci.insight.157013 PubMed
- [7] Qiqi Sun et al.. Sheng Wu Gong Cheng Xue Bao. 2022. [Regulation of inflammatory bowel disease by amino acids]. doi:10.13345/j.cjb.210697 PubMed
- [8] Débora Pereira Henriques et al.. Arq Gastroenterol. 2022. COMPLEMENTARY AND ALTERNATIVE MEDICINE USE IN BRAZILIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. doi:10.1590/S0004-2803.202203000-68 PubMed
- [9] Juliana Soares Severo et al.. Clin Nutr ESPEN. 2021. Effects of glutamine supplementation on inflammatory bowel disease: A systematic review of clinical trials. doi:10.1016/j.clnesp.2020.12.023 PubMed
- [10] Xiaoming Hu et al.. Gastroenterology. 2019. ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides. doi:10.1053/j.gastro.2018.11.033 PubMed
- [11] Jing Li et al.. J Cell Mol Med. 2019. Spontaneous colitis in IL-10-deficient mice was ameliorated via inhibiting glutaminase1. doi:10.1111/jcmm.14471 PubMed
- [12] Neeraj Narula et al.. Cochrane Database Syst Rev. 2018. Enteral nutritional therapy for induction of remission in Crohn's disease. doi:10.1002/14651858.CD000542.pub3 PubMed
- [13] Berkeley N Limketkai et al.. Gastroenterol Clin North Am. 2018. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. doi:10.1016/j.gtc.2017.09.007 PubMed
- [14] Toshimi Chiba et al.. Clin Med Insights Gastroenterol. 2018. Plasma-Free Amino Acid Profiles in Crohn's Disease: Relationship With the Crohn Disease Activity Index. doi:10.1177/1179552218791173 PubMed
- [15] Moftah H Alhagamhmad. Nutr Clin Pract. 2018. Enteral Nutrition in the Management of Crohn's Disease: Reviewing Mechanisms of Actions and Highlighting Potential Venues for Enhancing the Efficacy. doi:10.1002/ncp.10004 PubMed
- [16] Takayuki Yamamoto et al.. Curr Opin Biotechnol. 2017. Dietary and enteral interventions for Crohn's disease. doi:10.1016/j.copbio.2016.11.011 PubMed
- [17] Moftah H Alhagamhmad et al.. JPEN J Parenter Enteral Nutr. 2017. Exploring and Enhancing the Anti-Inflammatory Properties of Polymeric Formula. doi:10.1177/0148607115625627 PubMed
- [18] Sanne van Erp et al.. World J Gastroenterol. 2017. Cerebral magnetic resonance imaging in quiescent Crohn's disease patients with fatigue. doi:10.3748/wjg.v23.i6.1018 PubMed
- [19] Mohd Omar F Sikder et al.. AAPS J. 2017. The Na+/Cl--Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB0,+): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis. doi:10.1208/s12248-017-0164-7 PubMed
- [20] Anthony K Akobeng et al.. Cochrane Database Syst Rev. 2016. Glutamine for induction of remission in Crohn's disease. doi:10.1002/14651858.CD007348.pub2 PubMed
- [21] John K Triantafillidis et al.. Scand J Gastroenterol. 2014. The role of total parenteral nutrition in inflammatory bowel disease: current aspects. doi:10.3109/00365521.2013.860557 PubMed
- [22] Jaya Benjamin et al.. Dig Dis Sci. 2012. Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn's disease: a randomized controlled trial. doi:10.1007/s10620-011-1947-9 PubMed
- [23] Melissa A Smith et al.. Frontline Gastroenterol. 2012. Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence. doi:10.1136/flgastro-2011-100032 PubMed
- [24] Imad Elkhatib et al.. J Clin Gastroenterol. 2012. Plasma citrulline concentration as a marker for disease activity in patients with Crohn's disease. doi:10.1097/MCG.0b013e31822b80e0 PubMed
- [25] Alycia Leiby et al.. Pediatr Rev. 2012. Complementary, holistic, and integrative medicine: Crohn disease. doi:10.1542/pir.33-2-83 PubMed
- [26] Antonella Diamanti et al.. Int J Colorectal Dis. 2011. Plasma citrulline as surrogate marker of intestinal inflammation in pediatric and adolescent with Crohn's disease: preliminary report. doi:10.1007/s00384-011-1255-z PubMed
- [27] Moïse Coëffier et al.. Inflamm Bowel Dis. 2010. Potential for amino acids supplementation during inflammatory bowel diseases. doi:10.1002/ibd.21017 PubMed
- [28] M D Ballesteros Pomar et al.. Nutr Hosp. 2010. [Impact of nutritional treatment in the evolution of inflammatory bowel disease]. PubMed
- [29] Wael El-Matary. Nutr Clin Pract. 2009. Enteral nutrition as a primary therapy of Crohn's disease: the pediatric perspective. doi:10.1177/0884533608329660 PubMed
- [30] Stéphane Lecleire et al.. J Nutr. 2008. Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn's patients in association with changes in nuclear factor-kappaB … doi:10.3945/jn.108.099127 PubMed
- [31] Benoît Dupont et al.. Mol Nutr Food Res. 2008. Enteral nutrition in adult Crohn's disease: present status and perspectives. doi:10.1002/mnfr.200800093 PubMed
- [32] M Zachos et al.. Cochrane Database Syst Rev. 2007. Enteral nutritional therapy for induction of remission in Crohn's disease. doi:10.1002/14651858.CD000542.pub2 PubMed
- [33] Bernd Sido et al.. Dig Dis Sci. 2006. Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation? doi:10.1007/s10620-006-9473-x PubMed
- [34] Robert F Grimble. Curr Opin Gastroenterol. 2005. Immunonutrition. doi:10.1097/01.mog.0000153360.90653.82 PubMed
- [35] X Dray et al.. JPEN J Parenter Enteral Nutr. 2005. The use of enteral nutrition in the management of Crohn's disease in adults. doi:10.1177/01486071050290S4S166 PubMed
- [36] Arnaud Bourreille et al.. Clin Nutr. 2004. Glutamine metabolism in Crohn's disease: a stable isotope study. doi:10.1016/j.clnu.2004.03.002 PubMed
- [37] Barbara Kamińska et al.. Med Wieku Rozwoj. 2004. [Environmental factors in the etiopathology of inflammatory bowel syndrome]. PubMed
- [38] G L Ansaldo et al.. Ann Ital Chir. 2004. [Artificial nutrition in inflammatory bowel disease]. PubMed
- [39] J Goh et al.. Aliment Pharmacol Ther. 2003. Review article: nutrition and adult inflammatory bowel disease. doi:10.1046/j.1365-2036.2003.01482.x PubMed
- [40] F G Campos et al.. Nutr Hosp. 2003. Pharmacological nutrition in inflammatory bowel diseases. PubMed
- [41] Fábio Guilherme Campos et al.. Rev Hosp Clin Fac Med Sao Paulo. 2002. Inflammatory bowel diseases: principles of nutritional therapy. doi:10.1590/s0041-87812002000400009 PubMed
- [42] A I L Akobeng et al.. Scand J Gastroenterol. 2002. Low serum concentrations of insulin-like growth factor-I in children with active Crohn disease: effect of enteral nutritional support and glutamine … doi:10.1080/003655202762671521 PubMed
- [43] Khursheed N Jeejeebhoy. Curr Opin Gastroenterol. 2002. Enteral feeding. doi:10.1097/00001574-200203000-00010 PubMed
- [44] Khursheed N Jeejeebhoy. Curr Opin Clin Nutr Metab Care. 2002. Enteral feeding. doi:10.1097/00075197-200211000-00013 PubMed
- [45] M Zachos et al.. Cochrane Database Syst Rev. 2001. Enteral nutritional therapy for inducing remission of Crohn's disease. doi:10.1002/14651858.CD000542 PubMed
- [46] A K Akobeng et al.. J Pediatr Gastroenterol Nutr. 2000. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. doi:10.1097/00005176-200001000-00022 PubMed
- [47] S C Ling et al.. Curr Opin Clin Nutr Metab Care. 2000. Nutrition in inflammatory bowel disease. doi:10.1097/00075197-200009000-00003 PubMed
- [48] A K Akobeng et al.. JPEN J Parenter Enteral Nutr. 2000. Glutamine supplementation and intestinal permeability in Crohn's disease. doi:10.1177/0148607100024003196 PubMed
- [49] E Den Hond et al.. JPEN J Parenter Enteral Nutr. 1999. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. doi:10.1177/014860719902300107 PubMed
- [50] M M Duffy et al.. Dis Colon Rectum. 1998. Mucosal metabolism in ulcerative colitis and Crohn's disease. doi:10.1007/BF02237056 PubMed
- [51] D Schwab et al.. Z Gastroenterol. 1998. [Enteral nutrition in acute Crohn disease]. PubMed
- [52] W Dröge et al.. FASEB J. 1997. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction. doi:10.1096/fasebj.11.13.9367343 PubMed
- [53] R Meier. Schweiz Med Wochenschr Suppl. 1996. [Chronic inflammatory bowel diseases and nutrition]. PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.